Investigational drug · Phase 2
HDM2017
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for CRC, Colorectal Cancer, Colorectal Cancer Metastatic.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HDM2017"
First trial start
2026
Jul 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HDM2017", any sponsor or status.
Conditions studied
As listed on its trial records.
- CRC, Colorectal Cancer
- Colorectal Cancer Metastatic
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HDM2017" as an intervention, largest first.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07805551 · 220 participants (planned) · Start Aug 18, 2026 · Primary completion Aug 2030
Drug: HDM2017; Bevacizumab and 4 more · For: CRC, Colorectal Cancer
Sites: Beijing, China
- A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal CancerNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07621159 · 120 participants (planned) · Start Jul 15, 2026 · Primary completion Nov 1, 2027
Drug: HDM2017; Fruquintinib · For: Colorectal Cancer Metastatic
Sites: Beijing, China
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07274085 · 96 participants (planned) · Start Nov 18, 2025 · Primary completion Dec 31, 2026
Drug: HDM2017 · For: Solid Tumors
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.